Midhun Malla retweeted
Long-term follow-up of Temab-A with Bev vs SOC in 3L+ CRC: Updated results of a ph 1
#ESMO26 #ESMOAmbassadors
👉 mPFS: 6.8 vs 4.2 mo
👉 mOS: 14.7 vs 10.2 mo
👉 manageable safety
🧐Promising, ph-3 ongoing
@myESMO @ASCO
Midhun Malla retweeted
COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract Cancer | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO… @curecc @MDAndersonnews
Midhun Malla retweeted
PRABITAS phase III trial pragmatic trial enrolled 972 pts in 17M evaluating the schedule of TAS-102 + bev (2 weeks on/2 weeks off) vs. (1 week on/1 week off) which validates non-inferiority and less dose reductions validating our RWD approach in the US. #colorectal #cancer #ESMO2026 @OncoAlert
Midhun Malla retweeted
NICHE-2 | 5-year results
Just 2 doses of neoadjuvant nivo + 1 dose of ipi, followed by surgery...
Not a single recurrence after nearly 5 years of follow-up, and 5-year OS was 100%!
What more could we ask for?
I'm truly at a loss for words👏
thelancet.com/journals/lance…
Midhun Malla retweeted
RASolute 302 ph3 study: Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated mPDAC
#ESMO26 #ESMOAmbassadors
👉 mOS: 13.2 vs 6.7 mo
👉ORR improved in all RAS mutations
👉PFS & OS: small subgroups, favourable for all
🧐great data, consistent benefits for all pts
@myESMO @ASCO
Midhun Malla retweeted
May we cherish the memories we had together. Dr. Rachna Shroff said at this event the winner will always be the patients when we unite in the cause against cancer 🙏🙏
And yes @ronanhsieh this puts everything in perspective about what really is important in our lives
@OncoAlert
I was very lucky to meet @rachnatshroff for the first time during #ASCO26. We were having a fun debate about #HCC treatments with @jgong15, @MallaMidhun, @HardingJJMD, @HamediZahra, and Lipika Goyal, hosted by @MJHLifeSciences. Little did I know that it was one of her last public engagements.
I distinctly remember how kind she was to me, a junior faculty member. Despite being so established, she spent time giving me feedback on my two @SWOG proposals for biliary tract cancer. She told me my ideas were great and that we would discuss more at the hepatobiliary subcommittee meeting in June. However, she never showed up at meetings after ASCO. I still sent her all my proposal emails over the next three months. I was discussing with my buddy Gentry on the phone about scheduling a meeting with her because her advice was so valuable. Then, during the @_backtableONC podcast recording in San Diego, I learned that she was ill.
We all knew how great she was as a mentor. It is very sad that I won’t be able to learn more from her. But look at all the tweets about her in the last two days. She is still living in our memories, just like in the happy photos I am sharing below, once again.
And above all else, we need to spend more time with family and friends.
@TargetedOnc @OncLive @DaniCastilloMD
Midhun Malla retweeted
First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study - Journal of Hepatology journal-of-hepatology.eu/art…
Midhun Malla retweeted
🔥great news🔥
FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma
fda.gov/drugs/resources-info…
👉expanding options for patients with FGFR2 fusions!
@myESMO @ASCO @ILCAnews @EASLedu
Midhun Malla retweeted
Honored to speak at ACRSICON 2026 in Visakhapatnam on “De-escalation of Radiation Therapy in Rectal Adenocarcinoma.” Looking forward to discussing treatment personalization, organ preservation, biomarkers, and the evolving role of radiation with colleagues from across India.
Honored to speak at ACRSICON 2026 in Visakhapatnam on “De-escalation of Radiation Therapy in Rectal Adenocarcinoma.” Looking forward to discussing treatment personalization, organ preservation, biomarkers, and the evolving role of radiation with colleagues from across India.
📍 Visakhapatnam | Sept 18–20, 2026
#ACRSICON2026 #ACRSI #RectalCancer #GIOncology #PrecisionOncology
1
40
Midhun Malla retweeted
🧬 ctDNA in Resected BTC: Real-World Prognostic Value
A real-world analysis of 167 patients with resected stage I–III biliary tract cancer evaluated tumour-informed ctDNA for molecular residual disease and recurrence monitoring.
Key findings:
🔹 During the MRD window, ctDNA positivity was associated with inferior RFS (HR 9.33) and OS (HR 5.29).
🔹 During postdefinitive treatment surveillance, ctDNA positivity was associated with significantly shorter RFS (HR 18.12).
🔹 In multivariable analyses, ctDNA positivity was the most statistically significant prognostic factor associated with RFS.
🔹 Among 39 patients with clinical recurrence and a preceding positive ctDNA result, ctDNA detected relapse a median of 3.7 months before radiographic recurrence.
🔹 During surveillance, ctDNA showed 80.6% sensitivity and 95.7% specificity for detecting relapse.
🔹 CA19-9 and CEA were not significantly prognostic during either the MRD or surveillance periods.
💡 Takeaway: ctDNA showed strong prognostic value for postoperative risk stratification and recurrence monitoring in resected BTC. Prospective studies are needed to determine whether ctDNA-guided strategies can improve clinical outcomes.
@MallaMidhun @JeniferFerguson @MaenAbdelrahim @oncodaily
⚡️oncodaily.com/oncolibrary/ga…
#BTC #ctDNA #OncoDaily
Midhun Malla retweeted
🔟Must-Read Posts in GI Oncology This Week | Last Week of July
This week’s selection covers:
• ARISTOTLE and AI-derived tumour cell density in rectal cancer
• Surgery after systemic therapy in locally advanced BTC
• TESAR after local excision of early rectal cancer
• AI pathology for adjuvant chemotherapy benefit in pancreatic cancer
• DESTINY-PanTumor02: T-DXd in HER2-expressing BTC and pancreatic tumors
• CLARITY-Gastric 01: AZD0901 in CLDN18.2+ gastric/GEJ cancer
• TriNetX real-world data: atezo/bev vs durva/treme in advanced HCC
• AI relapse prediction in stage II bowel cancer
• COMMIT in MSI-H/dMMR metastatic CRC
• ctDNA in resected BTC
@MontefioreD @casadei_gardini @NelsonDusetti @dr_yakupergun @KoheiShitara @hongjaechon @Patriciahaueiss @MallaMidhun @GIMedOnc
Read more on OncoDaily - oncodaily.com/oncolibrary/ga…
#GIOncology #OncoDaily
Midhun Malla retweeted
Now FDA finally delivered!!
Please welcome 🎂 the new birth of 💫 “RASONque”
Congrats 🎉🎊 to every investigator, nursing teams, research teams and courageous patients! #pancreaticcancer #PDAC
@MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @EileenMOReilly @MichaelMayMD @MarcHilmi @FiyinfoluB @schoenfeld_j @AnupriyaSingha9
fda.gov/news-events/press-an…
Midhun Malla retweeted
Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced HCC (TALENTOP): a multicentre phs 3 trial
@TheLancet
doi.org/10.1016/S0140-6736(2…
👉supports neoadjuvant concepts in HCC
👉response adopted treatment
@myESMO @EASLnews @ILCAnews
Midhun Malla retweeted
Save the Date 🌵✨
MaTOS GI Edition is coming to Tucson, Arizona, July 22–25, 2027, at The Ritz-Carlton, Dove Mountain.
Join leading experts in gastrointestinal oncology for an educational experience focused on the latest advances, emerging therapies, and evolving standards of care.
📅 July 22–25, 2027
📍 The Ritz-Carlton, Dove Mountain
📍 Marana, Tucson, Arizona
Registration will open once the conference website goes live.
Stay tuned for updates and be among the first to register.
#MaTOS #MaTOSGI #Oncology #GIOncology #GastrointestinalCancer #CancerEducation #MedicalEducation #OncologyConference #Tucson #Arizona #SaveTheDate
@lowellanthonymd
@RobertoBoreaMD
@AmanChauhanMD
@mikecusnir
@DrElkhoueiry
@ZhiVenFongMD
@anup_kasi
@MallaMidhun
@rutikamehtaMD
@Sarbaji85064063
@paphilip
@LuisraezMD
@ibrahimsahinMD1
@EddieSantosMD @edgardo_ny
@kais_Zakharia
📢 Excited to share our latest publication on ctDNA in resected biliary tract cancer (BTC).
🧬 Largest real-world BTC ctDNA study to date (to our knowledge): 167 patients and 751 longitudinal plasma samples.
doi.org/10.1016/j.esmogo.202…
🚀 Results provide a strong foundation for prospective ctDNA-guided clinical trials in BTC.
🙏 A heartfelt thank you to all our patients, and study teams across participating institutions. @MaenAbdelrahim #RichardKim @docsudhakodali1 @AmitMahipal1979 @NateraOncology
1
1
148
This publication is the result of years of dedication, teamwork, and perseverance.👏 Proud to be part of this incredible collaborative effort advancing precision oncology for patients with BTC. #precisionmedicine #circulatingtumorDNA
2
76





























